452 episodes
A focus on cutting edge science and a busy year of presentations and partnerships has made Circio not just one of the fastest growing biotech companies in the Nordic region, but in all of Europe
09/01/2026 | 13 mins.Co-Founder & CEO Erik Wiklund highlights the potential of circular RNA and walks us through the work Circio is doing in gene and cell therapy, including heart and eye indications, CNS, and in vivo CAR-T. The company has raised approximately $65M USD this year, putting at the top of European biotech raises.Sweden's BioArtic founded the science behind the Alzheimer's medicine Leqembi - 2026 has been busy with a Parkinson's program and a host of partnerships for it brain transporter technology advancing
09/01/2026 | 13 mins.CEO Gunilla Osswald talks about the recently approved self-administered subcu formulation of lecanemab, called IQLIK, and updates us on a Parkinson's program that is moving along. Plus, how BioArctic's transferrin based brain transporter technology is different than others, which has resulted in numerous prestigious pharma partnerships.Remix Therapeutics announced earlier this summer plans to go public via a reverse merger - it's on the back of clinical data that was presented for its RNA modulator at ASCO
08/26/2026 | 9 mins.Co-Founder and CEO Pete Smith describes how Remix uses small molecules to stop the transcription of disease causing mRNAs. The lead program targets MYB and is in a phase 1/2 for adenoid cystic carcinoma. The reverse merger could close towards the end of year.Two fathers of children with rare diseases talk about starting biotech companies to try to create new therapies for their family members and others
08/26/2026 | 40 mins.Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome.LifeMine Therapeutics announced a $263M raise today to help accelerate the development of its novel calcineurin activation inhibitor that aims to radically change the profile of organ transplants
08/06/2026 | 16 mins.Co-Founder, President & CEO Greg Verdine describes the toxicity issues associated with the immuosupressive drugs that transplant recipients currently receive, and explains how LIFE-001 is different. Plus, given how the therapy is designed to safely prevent T-cell activation and proliferation, there could also ultimately be an autoimmune use case as well.
Ground TruthsHealth & Wellness, Life Sciences, Medicine, Science
Speaking of PsychologyHealth & Wellness, Life Sciences, Mental Health, Science
The Quanta PodcastLife Sciences, Science
Health Optimization Medicine PodcastAlternative Health, Health & Wellness, Life Sciences, Science
Science FridayEarth Sciences, Life Sciences, Natural Sciences, Science
Science of Perception BoxHealth & Wellness, Life Sciences, Mental Health, Science
UnexplainableLife Sciences, Science
Stuff To Blow Your MindLife Sciences, Science
The Joy of WhyLife Sciences, Science
Short WaveDaily News, Life Sciences, News, Science
Listen to BiotechTV - News, Ground Truths and many other podcasts from around the world with the radio.net app
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
BiotechTV - News
download the app,
start listening.
USA